trial

Tocilizumab as Add-On Treatment For Residual Positive, Negative, and Cognitive Symptoms of Schizophrenia

NCTId NCT02034474
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 59 (actual)
Sponsored by New York State Psychiatric Institute, Washington Heights Community Service
Primary completion 2017-02-06
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
59 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2014-02
Primary completion
2017-02-06
Eligibility
ALL · 18 Years · 59 Years

Interventions & indications

Drugs
Tocilizumab

Sponsors

New York State Psychiatric Institute, Washington Heights Community ServiceLead Sponsor
Stanley Medical Research InstituteCollaborator

Investigators

1
Ragy R Girgis, MDPrincipal Investigator

Sites

1 total
New York, United States

Facts & assertions

4 sourced
Enrollment
59
Phase
PHASE4
Primary Completion Date
2017-02-06
Status
COMPLETED
relationships
The graph out of here
drug
Tocilizumab
drug
lead_sponsor
New York State Psychiatric Institute, Washington Heights Community Service
company
collaborator
Stanley Medical Research Institute
company
indication
Schizophrenia
indication
Schizoaffective Disorder
indication
Schizophrenia
indication
investigator
Ragy R Girgis, MD
person